Triptodur Kit is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 30, 2029. Details of Triptodur Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10166181 | Slow release pharmaceutical composition made of microgranules |
Jun, 2029
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Triptodur Kit's patents.
Latest Legal Activities on Triptodur Kit's Patents
Given below is the list of recent legal activities going on the following patents of Triptodur Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Jul, 2022 | US10166181 |
| Post Issue Communication - Certificate of Correction | 08 Jan, 2020 | US10166181 |
| Email Notification Critical | 27 Sep, 2019 | US10166181 |
| Mail-Petition Decision - Dismissed Critical | 24 Sep, 2019 | US10166181 |
| Petition Decision - Dismissed Critical | 23 Sep, 2019 | US10166181 |
| Email Notification Critical | 06 Mar, 2019 | US10166181 |
| Change in Power of Attorney (May Include Associate POA) Critical | 06 Mar, 2019 | US10166181 |
| Petition Entered | 25 Feb, 2019 | US10166181 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Jan, 2019 | US10166181 |
| Recordation of Patent Grant Mailed Critical | 01 Jan, 2019 | US10166181 |
FDA has granted several exclusivities to Triptodur Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Triptodur Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Triptodur Kit.
Exclusivity Information
Triptodur Kit holds 3 exclusivities. All of its exclusivities have expired in 2024. Details of Triptodur Kit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 29, 2020 |
| Orphan Drug Exclusivity(ODE) | Jun 29, 2024 |
| Orphan Drug Exclusivity(ODE-149) | Jun 29, 2024 |
Several oppositions have been filed on Triptodur Kit's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Triptodur Kit's generic, the next section provides detailed information on ongoing and past EP oppositions related to Triptodur Kit patents.
Triptodur Kit's Oppositions Filed in EPO
Triptodur Kit has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 13, 2017, by Generics (Uk) Ltd. This opposition was filed on patent number EP08763237A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP12172232A | Apr, 2019 | Generics [UK] Ltd | Granted and Under Opposition |
| EP08763237A | Sep, 2017 | Ferring B.V. | Revoked |
| EP08763237A | Sep, 2017 | Generics (UK) Ltd | Revoked |
US patents provide insights into the exclusivity only within the United States, but Triptodur Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Triptodur Kit's family patents as well as insights into ongoing legal events on those patents.
Triptodur Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Triptodur Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 30, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Triptodur Kit Generics:
There are no approved generic versions for Triptodur Kit as of now.
Alternative Brands for Triptodur Kit
There are several other brand drugs using the same active ingredient (Triptorelin Pamoate) as Triptodur Kit. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Verity |
|
About Triptodur Kit
Triptodur Kit is a drug owned by Azurity Pharmaceuticals Inc. Triptodur Kit uses Triptorelin Pamoate as an active ingredient. Triptodur Kit was launched by Azurity in 2017.
Approval Date:
Triptodur Kit was approved by FDA for market use on 29 June, 2017.
Active Ingredient:
Triptodur Kit uses Triptorelin Pamoate as the active ingredient. Check out other Drugs and Companies using Triptorelin Pamoate ingredient
Dosage:
Triptodur Kit is available in for suspension, extended release form for intramuscular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 22.5MG BASE/VIAL | FOR SUSPENSION, EXTENDED RELEASE | Prescription | INTRAMUSCULAR |